Kiss C

No ORCID on file · 2 papers in corpus · active 2022-2025
2025
Efficacy of regular prophylaxis with a plasma-derived von Willebrand factor/factor VIII concentrate with a 1:1 activity ratio in reducing heavy menstrual bleeding in girls/women with von Willebrand disease.
AJOG global reports ·doi:10.1016/j.xagr.2025.100501

BackgroundHeavy menstrual bleeding is the dominant symptom in girls/women with von Willebrand disease (VWD), affecting ∼80 to 90%. Female patients with VWD are typically diagnosed later than males, despite the disproportionate impact of hea…

2022
Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Primary Human Endometrial Carcinomas: Novel Therapeutic Approaches.
Molecules (Basel, Switzerland) ·doi:10.3390/molecules27092671

Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of various tumors, including endometrial carcinomas (EC). However, tumoral receptors that mediate the antiproliferative effects of GHRH antagonists in human ECs have …